TY - JOUR AU - Hurvitz, S. A. AU - Pietras, R. J. PY - 2008 DA - 2008// TI - Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions JO - Cancer VL - 113 UR - https://doi.org/10.1002/cncr.23875 DO - 10.1002/cncr.23875 ID - Hurvitz2008 ER - TY - JOUR AU - Briest, S. AU - Stearns, V. PY - 2009 DA - 2009// TI - Tamoxifen metabolism and its effect on endocrine treatment of breast cancer JO - Clin Adv Hematol Oncol VL - 7 ID - Briest2009 ER - TY - JOUR AU - Lonning, P. E. PY - 2007 DA - 2007// TI - Adjuvant endocrine treatment of early breast cancer JO - Hematol Oncol Clin North Am VL - 21 UR - https://doi.org/10.1016/j.hoc.2007.03.002 DO - 10.1016/j.hoc.2007.03.002 ID - Lonning2007 ER - TY - JOUR AU - Delozier, T. AU - Spielmann, M. AU - Mace-Lesec'h, J. AU - Janvier, M. AU - Hill, C. AU - Asselain, B. AU - Julien, J. P. AU - Weber, B. AU - Mauriac, L. AU - Petit, J. C. AU - Kerbrat, P. AU - Malhaire, J. P. AU - Vennin, P. AU - Leduc, B. AU - Namer, M. PY - 2000 DA - 2000// TI - Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment, Federation Nationale des Centres de Lutte Contre le Cancer Breast Group JO - J Clin Oncol VL - 18 ID - Delozier2000 ER - TY - JOUR AU - van Agthoven, T. AU - Sieuwerts, A. M. AU - Meijer-van Gelder, M. E. AU - Look, M. P. AU - Smid, M. AU - Veldscholte, J. AU - Sleijfer, S. AU - Foekens, J. A. AU - Dorssers, L. C. PY - 2009 DA - 2009// TI - Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.17.1462 DO - 10.1200/JCO.2008.17.1462 ID - van Agthoven2009 ER - TY - JOUR AU - Santen, R. J. AU - Fan, P. AU - Zhang, Z. AU - Bao, Y. AU - Song, R. X. AU - Yue, W. PY - 2009 DA - 2009// TI - Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells JO - Steroids VL - 74 UR - https://doi.org/10.1016/j.steroids.2008.11.020 DO - 10.1016/j.steroids.2008.11.020 ID - Santen2009 ER - TY - JOUR AU - Dihge, L. AU - Bendahl, P. O. AU - Grabau, D. AU - Isola, J. AU - Lovgren, K. AU - Ryden, L. AU - Ferno, M. PY - 2008 DA - 2008// TI - Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer JO - Breast Cancer Res Treat VL - 109 UR - https://doi.org/10.1007/s10549-007-9645-1 DO - 10.1007/s10549-007-9645-1 ID - Dihge2008 ER - TY - JOUR AU - Fan, P. AU - Wang, J. AU - Santen, R. J. AU - Yue, W. PY - 2007 DA - 2007// TI - Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-1020 DO - 10.1158/0008-5472.CAN-06-1020 ID - Fan2007 ER - TY - JOUR AU - Chong, K. AU - Subramanian, A. AU - Sharma, A. AU - Mokbel, K. PY - 2011 DA - 2011// TI - Measuring IGF-1, ER-alpha and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer JO - Anticancer Res VL - 31 ID - Chong2011 ER - TY - JOUR AU - Frogne, T. AU - Benjaminsen, R. V. AU - Sonne-Hansen, K. AU - Sorensen, B. S. AU - Nexo, E. AU - Laenkholm, A. V. AU - Rasmussen, L. M. AU - Riese, D. J. AU - de Cremoux, P. AU - Stenvang, J. AU - Lykkesfeldt, A. E. PY - 2009 DA - 2009// TI - Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant JO - Breast Cancer Res Treat VL - 114 UR - https://doi.org/10.1007/s10549-008-0011-8 DO - 10.1007/s10549-008-0011-8 ID - Frogne2009 ER - TY - JOUR AU - Normanno, N. AU - Campiglio, M. AU - Maiello, M. R. AU - De Luca, A. AU - Mancino, M. AU - Gallo, M. AU - D'Alessio, A. AU - Menard, S. PY - 2008 DA - 2008// TI - Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling JO - Breast Cancer Res Treat VL - 112 UR - https://doi.org/10.1007/s10549-007-9830-2 DO - 10.1007/s10549-007-9830-2 ID - Normanno2008 ER - TY - JOUR AU - Normanno, N. AU - De Luca, A. AU - Maiello, M. R. AU - Campiglio, M. AU - Napolitano, M. AU - Mancino, M. AU - Carotenuto, A. AU - Viglietto, G. AU - Menard, S. PY - 2006 DA - 2006// TI - The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib JO - J Cell Physiol VL - 207 UR - https://doi.org/10.1002/jcp.20588 DO - 10.1002/jcp.20588 ID - Normanno2006 ER - TY - JOUR AU - Guo, L. AU - Abraham, J. AU - Flynn, D. C. AU - Castranova, V. AU - Shi, X. AU - Qian, Y. PY - 2007 DA - 2007// TI - Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phospho-p70S6K proteins JO - Int J Biol Markers VL - 22 ID - Guo2007 ER - TY - JOUR AU - Prossnitz, E. R. AU - Arterburn, J. B. AU - Smith, H. O. AU - Oprea, T. I. AU - Sklar, L. A. AU - Hathaway, H. J. PY - 2008 DA - 2008// TI - Estrogen signaling through the transmembrane G protein-coupled receptor GPR30 JO - Annu Rev Physiol VL - 70 UR - https://doi.org/10.1146/annurev.physiol.70.113006.100518 DO - 10.1146/annurev.physiol.70.113006.100518 ID - Prossnitz2008 ER - TY - JOUR AU - Wei, Y. AU - Zhang, Z. AU - Liao, H. AU - Wu, L. AU - Wu, X. AU - Zhou, D. AU - Xi, X. AU - Zhu, Y. AU - Feng, Y. PY - 2012 DA - 2012// TI - Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation JO - Oncol Rep VL - 27 ID - Wei2012 ER - TY - JOUR AU - Arias-Pulido, H. AU - Royce, M. AU - Gong, Y. AU - Joste, N. AU - Lomo, L. AU - Lee, S. J. AU - Chaher, N. AU - Verschraegen, C. AU - Lara, J. AU - Prossnitz, E. R. AU - Cristofanilli, M. PY - 2010 DA - 2010// TI - GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer JO - Breast Cancer Res Treat VL - 123 UR - https://doi.org/10.1007/s10549-009-0631-7 DO - 10.1007/s10549-009-0631-7 ID - Arias-Pulido2010 ER - TY - JOUR AU - Johnston, S. R. AU - Haynes, B. P. AU - Smith, I. E. AU - Jarman, M. AU - Sacks, N. P. AU - Ebbs, S. R. AU - Dowsett, M. PY - 1993 DA - 1993// TI - Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration JO - Lancet VL - 342 UR - https://doi.org/10.1016/S0140-6736(05)80088-1 DO - 10.1016/S0140-6736(05)80088-1 ID - Johnston1993 ER - TY - JOUR AU - Maggiolini, M. AU - Picard, D. PY - 2010 DA - 2010// TI - The unfolding stories of GPR30, a new membrane-bound estrogen receptor JO - J Endocrinol VL - 204 UR - https://doi.org/10.1677/JOE-09-0242 DO - 10.1677/JOE-09-0242 ID - Maggiolini2010 ER - TY - JOUR AU - Thomas, P. AU - Pang, Y. AU - Filardo, E. J. AU - Dong, J. PY - 2005 DA - 2005// TI - Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells JO - Endocrinology VL - 146 UR - https://doi.org/10.1210/en.2004-1064 DO - 10.1210/en.2004-1064 ID - Thomas2005 ER - TY - JOUR AU - Filardo, E. J. AU - Quinn, J. A. AU - Bland, K. I. AU - Frackelton, A. R. PY - 2000 DA - 2000// TI - Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF JO - Mol Endocrinol VL - 14 UR - https://doi.org/10.1210/mend.14.10.0532 DO - 10.1210/mend.14.10.0532 ID - Filardo2000 ER - TY - JOUR AU - Filardo, E. J. AU - Quinn, J. A. AU - Frackelton, A. R. AU - Bland, K. I. PY - 2002 DA - 2002// TI - Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis JO - Mol Endocrinol VL - 16 UR - https://doi.org/10.1210/mend.16.1.0758 DO - 10.1210/mend.16.1.0758 ID - Filardo2002 ER - TY - JOUR AU - Coser, K. R. AU - Wittner, B. S. AU - Rosenthal, N. F. AU - Collins, S. C. AU - Melas, A. AU - Smith, S. L. AU - Mahoney, C. J. AU - Shioda, K. AU - Isselbacher, K. J. AU - Ramaswamy, S. AU - Shioda, T. PY - 2009 DA - 2009// TI - Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor JO - Proc Natl Acad Sci USA VL - 106 UR - https://doi.org/10.1073/pnas.0907560106 DO - 10.1073/pnas.0907560106 ID - Coser2009 ER - TY - JOUR AU - Massarweh, S. AU - Osborne, C. K. AU - Jiang, S. AU - Wakeling, A. E. AU - Rimawi, M. AU - Mohsin, S. K. AU - Hilsenbeck, S. AU - Schiff, R. PY - 2006 DA - 2006// TI - Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-4045 DO - 10.1158/0008-5472.CAN-05-4045 ID - Massarweh2006 ER - TY - JOUR AU - Mizukami, Y. PY - 2010 DA - 2010// TI - In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo JO - Endocr J VL - 57 UR - https://doi.org/10.1507/endocrj.K09E-332 DO - 10.1507/endocrj.K09E-332 ID - Mizukami2010 ER - TY - JOUR AU - Wang, D. AU - Hu, L. AU - Zhang, G. AU - Zhang, L. AU - Chen, C. PY - 2010 DA - 2010// TI - G protein-coupled receptor 30 in tumor development JO - Endocrine VL - 38 UR - https://doi.org/10.1007/s12020-010-9363-z DO - 10.1007/s12020-010-9363-z ID - Wang2010 ER - TY - JOUR AU - Prossnitz, E. R. AU - Maggiolini, M. PY - 2009 DA - 2009// TI - Mechanisms of estrogen signaling and gene expression via GPR30 JO - Mol Cell Endocrinol VL - 308 UR - https://doi.org/10.1016/j.mce.2009.03.026 DO - 10.1016/j.mce.2009.03.026 ID - Prossnitz2009 ER - TY - JOUR AU - Ariazi, E. A. AU - Brailoiu, E. AU - Yerrum, S. AU - Shupp, H. A. AU - Slifker, M. J. AU - Cunliffe, H. E. AU - Black, M. A. AU - Donato, A. L. AU - Arterburn, J. B. AU - Oprea, T. I. AU - Prossnitz, E. R. AU - Dun, N. J. AU - Jordan, V. C. PY - 2010 DA - 2010// TI - The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3068 DO - 10.1158/0008-5472.CAN-09-3068 ID - Ariazi2010 ER - TY - JOUR AU - Vivacqua, A. AU - Lappano, R. AU - De Marco, P. AU - Sisci, D. AU - Aquila, S. AU - De Amicis, F. AU - Fuqua, S. A. AU - Ando, S. AU - Maggiolini, M. PY - 2009 DA - 2009// TI - G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells JO - Mol Endocrinol VL - 23 UR - https://doi.org/10.1210/me.2009-0120 DO - 10.1210/me.2009-0120 ID - Vivacqua2009 ER - TY - JOUR AU - Pandey, D. P. AU - Lappano, R. AU - Albanito, L. AU - Madeo, A. AU - Maggiolini, M. AU - Picard, D. PY - 2009 DA - 2009// TI - Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF JO - EMBO J VL - 28 UR - https://doi.org/10.1038/emboj.2008.304 DO - 10.1038/emboj.2008.304 ID - Pandey2009 ER - TY - JOUR AU - Burdette-Radoux, S. AU - Muss, H. B. PY - 2009 DA - 2009// TI - A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy? JO - Clin Breast Cancer VL - 9 UR - https://doi.org/10.3816/CBC.2009.s.004 DO - 10.3816/CBC.2009.s.004 ID - Burdette-Radoux2009 ER - TY - JOUR AU - Massarweh, S. AU - Osborne, C. K. AU - Creighton, C. J. AU - Qin, L. AU - Tsimelzon, A. AU - Huang, S. AU - Weiss, H. AU - Rimawi, M. AU - Schiff, R. PY - 2008 DA - 2008// TI - Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-2707 DO - 10.1158/0008-5472.CAN-07-2707 ID - Massarweh2008 ER - TY - JOUR AU - Yue, W. AU - Fan, P. AU - Wang, J. AU - Li, Y. AU - Santen, R. J. PY - 2007 DA - 2007// TI - Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells JO - J Steroid Biochem Mol Biol VL - 106 UR - https://doi.org/10.1016/j.jsbmb.2007.05.008 DO - 10.1016/j.jsbmb.2007.05.008 ID - Yue2007 ER - TY - JOUR AU - Filardo, E. J. AU - Graeber, C. T. AU - Quinn, J. A. AU - Resnick, M. B. AU - Giri, D. AU - DeLellis, R. A. AU - Steinhoff, M. M. AU - Sabo, E. PY - 2006 DA - 2006// TI - Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0860 DO - 10.1158/1078-0432.CCR-06-0860 ID - Filardo2006 ER - TY - JOUR AU - Rae, J. M. AU - Johnson, M. D. PY - 2005 DA - 2005// TI - What does an orphan G-protein-coupled receptor have to do with estrogen? JO - Breast Cancer Res VL - 7 UR - https://doi.org/10.1186/bcr1330 DO - 10.1186/bcr1330 ID - Rae2005 ER - TY - JOUR AU - Li, Y. AU - Birnbaumer, L. AU - Teng, C. T. PY - 2010 DA - 2010// TI - Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1 JO - Mol Endocrinol VL - 24 UR - https://doi.org/10.1210/me.2009-0148 DO - 10.1210/me.2009-0148 ID - Li2010 ER - TY - JOUR AU - Filardo, E. J. AU - Quinn, J. A. AU - Sabo, E. PY - 2008 DA - 2008// TI - Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor JO - Steroids VL - 73 UR - https://doi.org/10.1016/j.steroids.2007.12.025 DO - 10.1016/j.steroids.2007.12.025 ID - Filardo2008 ER - TY - JOUR AU - Filardo, E. J. PY - 2002 DA - 2002// TI - Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer JO - J Steroid Biochem Mol Biol VL - 80 UR - https://doi.org/10.1016/S0960-0760(01)00190-X DO - 10.1016/S0960-0760(01)00190-X ID - Filardo2002 ER - TY - JOUR AU - Vivacqua, A. AU - Romeo, E. AU - De Marco, P. AU - De Francesco, E. M. AU - Abonante, S. AU - Maggiolini, M. PY - 2012 DA - 2012// TI - GPER mediates the Egr-1 expression induced by 17beta-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells JO - Breast Cancer Res Treat VL - 133 UR - https://doi.org/10.1007/s10549-011-1901-8 DO - 10.1007/s10549-011-1901-8 ID - Vivacqua2012 ER - TY - JOUR AU - Shi, L. AU - Dong, B. AU - Li, Z. AU - Lu, Y. AU - Ouyang, T. AU - Li, J. AU - Wang, T. AU - Fan, Z. AU - Fan, T. AU - Lin, B. AU - Wang, Z. AU - Xie, Y. PY - 2009 DA - 2009// TI - Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.17.2254 DO - 10.1200/JCO.2008.17.2254 ID - Shi2009 ER - TY - JOUR AU - Shi, Y. E. AU - Chen, Y. AU - Dackour, R. AU - Potters, L. AU - Wang, S. AU - Ding, Q. AU - Wang, Z. AU - Liu, Y. E. PY - 2010 DA - 2010// TI - Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha JO - Am J Pathol VL - 177 UR - https://doi.org/10.2353/ajpath.2010.100061 DO - 10.2353/ajpath.2010.100061 ID - Shi2010 ER - TY - JOUR AU - Sengupta, S. AU - Jordan, V. C. PY - 2008 DA - 2008// TI - Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance JO - Adv Exp Med Biol VL - 630 UR - https://doi.org/10.1007/978-0-387-78818-0_13 DO - 10.1007/978-0-387-78818-0_13 ID - Sengupta2008 ER - TY - JOUR AU - Dragowska, W. H. AU - Verreault, M. AU - Yapp, D. T. AU - Warburton, C. AU - Edwards, L. AU - Ramsay, E. C. AU - Huxham, L. A. AU - Minchinton, A. I. AU - Gelmon, K. AU - Bally, M. B. PY - 2007 DA - 2007// TI - Decreased levels of hypoxic cells in gefitinib treated ER + HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin JO - Breast Cancer Res Treat VL - 106 UR - https://doi.org/10.1007/s10549-007-9502-2 DO - 10.1007/s10549-007-9502-2 ID - Dragowska2007 ER - TY - JOUR AU - Kleuser, B. AU - Malek, D. AU - Gust, R. AU - Pertz, H. H. AU - Potteck, H. PY - 2008 DA - 2008// TI - 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30 JO - Mol Pharmacol VL - 74 UR - https://doi.org/10.1124/mol.108.046854 DO - 10.1124/mol.108.046854 ID - Kleuser2008 ER - TY - JOUR AU - Li, Z. AU - Hosoi, Y. AU - Cai, K. AU - Tanno, Y. AU - Matsumoto, Y. AU - Enomoto, A. AU - Morita, A. AU - Nakagawa, K. AU - Miyagawa, K. PY - 2006 DA - 2006// TI - Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation JO - Biochem Biophys Res Commun VL - 341 UR - https://doi.org/10.1016/j.bbrc.2005.12.193 DO - 10.1016/j.bbrc.2005.12.193 ID - Li2006 ER - TY - JOUR AU - Ignatov, A. AU - Ignatov, T. AU - Roessner, A. AU - Costa, S. D. AU - Kalinski, T. PY - 2010 DA - 2010// TI - Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells JO - Breast Cancer Res Treat VL - 123 UR - https://doi.org/10.1007/s10549-009-0624-6 DO - 10.1007/s10549-009-0624-6 ID - Ignatov2010 ER - TY - JOUR AU - McCubrey, J. A. AU - Steelman, L. S. AU - Abrams, S. L. AU - Lee, J. T. AU - Chang, F. AU - Bertrand, F. E. AU - Navolanic, P. M. AU - Terrian, D. M. AU - Franklin, R. A. AU - D'Assoro, A. B. AU - Salisbury, J. L. AU - Mazzarino, M. C. AU - Stivala, F. AU - Libra, M. PY - 2006 DA - 2006// TI - Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance JO - Adv Enzyme Regul VL - 46 UR - https://doi.org/10.1016/j.advenzreg.2006.01.004 DO - 10.1016/j.advenzreg.2006.01.004 ID - McCubrey2006 ER - TY - JOUR AU - Shou, J. AU - Massarweh, S. AU - Osborne, C. K. AU - Wakeling, A. E. AU - Ali, S. AU - Weiss, H. AU - Schiff, R. PY - 2004 DA - 2004// TI - Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh166 DO - 10.1093/jnci/djh166 ID - Shou2004 ER - TY - JOUR AU - Cui, Y. AU - Parra, I. AU - Zhang, M. AU - Hilsenbeck, S. G. AU - Tsimelzon, A. AU - Furukawa, T. AU - Horii, A. AU - Zhang, Z. Y. AU - Nicholson, R. I. AU - Fuqua, S. A. PY - 2006 DA - 2006// TI - Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-3243 DO - 10.1158/0008-5472.CAN-05-3243 ID - Cui2006 ER - TY - JOUR AU - Swanton, C. AU - Downward, J. PY - 2008 DA - 2008// TI - Unraveling the complexity of endocrine resistance in breast cancer by functional genomics JO - Cancer Cell VL - 13 UR - https://doi.org/10.1016/j.ccr.2008.01.021 DO - 10.1016/j.ccr.2008.01.021 ID - Swanton2008 ER - TY - JOUR AU - Fan, P. AU - Yue, W. AU - Wang, J. P. AU - Aiyar, S. AU - Li, Y. AU - Kim, T. H. AU - Santen, R. J. PY - 2009 DA - 2009// TI - Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models JO - Endocrinology VL - 150 UR - https://doi.org/10.1210/en.2008-1195 DO - 10.1210/en.2008-1195 ID - Fan2009 ER -